title: Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.
abstract: Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.
authors.affiliation: Renal Unit, King's College Hospital, London, UK. Iain.macdougall@nhs.net
authors.forename: Iain C
authors.initials: IC
authors.lastname: Macdougall
authors.forename: Simon D
authors.initials: SD
authors.lastname: Roger
authors.forename: Angel
authors.initials: A
authors.lastname: de Francisco
authors.forename: David J A
authors.initials: DJ
authors.lastname: Goldsmith
authors.forename: Huub
authors.initials: H
authors.lastname: Schellekens
authors.forename: Hans
authors.initials: H
authors.lastname: Ebbers
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Jelkmann
authors.forename: Gérard
authors.initials: G
authors.lastname: London
authors.forename: Nicole
authors.initials: N
authors.lastname: Casadevall
authors.forename: Walter H
authors.initials: WH
authors.lastname: Hörl
authors.forename: David M
authors.initials: DM
authors.lastname: Kemeny
authors.forename: Carol
authors.initials: C
authors.lastname: Pollock
mesh_terms: D002626:Chemistry, Pharmaceutical; D064420:Drug-Related Side Effects and Adverse Reactions; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D055503:Protein Multimerization / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D012010:Red-Cell Aplasia, Pure / Q000209:etiology* / Q000276:immunology*; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D013997:Time Factors
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa